Polar Capital Global Healthcare

Top Ten Equity Holdings and Exposures
RNS Number : 6674H
Polar Capital Global Health Tst PLC
04 December 2020
 

4th December 2020

 

Polar Capital Global Healthcare Trust plc (the "Company")

 

Top Ten Equity Holdings and Sector and Geographic Exposure as at 30th November 2020. The full portfolio listing as at 30th October 2020 is available from the company's website

 

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 30th November 2020 the top ten equity holdings and the sector and geographic breakdown were as follows:

 

Top 10 Holdings         

%

UnitedHealth Group

4.7%

AstraZeneca

4.1%

Bristol Myers Squibb

4.1%

Medtronic

3.9%

Novo Nordisk A/S

3.7%

Koninklijke Philips

3.5%

Eli Lilly & Co

3.4%

Roche

3.4%

Amgen

3.4%

Syneos Health

3.3%

Total

37.4%

 

 

Sector Exposure

%

Pharmaceuticals

26.8%

Healthcare Equipment

23.4%

Biotechnology

16.6%

Life Sciences Tools & Services

12.0%

Managed Healthcare

10.0%

Healthcare Technology

3.6%

Healthcare Supplies

3.4%

Healthcare Services

3.0%

Healthcare Distributors

2.9%

Cash

-1.8%

Total

100.0%

 

 

Geographic Exposure

%

United States

61.5%

Germany

6.6%

United Kingdom

6.0%

Japan

5.7%

Switzerland

5.3%

Denmark

5.1%

Netherlands

4.6%

Ireland

4.4%

France

2.7%

Cash

-1.8%

Total

100.0%

 

 

 

Gearing Ratio as calculated in accordance with the guidelines of the Association of Investment Companies, was 1.8%. Gearing is made up of structural debt provided by the subsidiary company PCGH ZDP plc, through the issue of zero dividend preference (ZDP) shares.

 

The ZDP asset cover as at 30th November 2020 was 9.20x.

 

 

The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager.  www.Polarcapitalhealthcaretrust.com

 

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUMZMGZNDMGGZM